A medium-sized company whose market valuation 6,982.53 crores, Procter & Gamble Health Limited works in the pharmaceutical industry. One of the largest VMS companies in India, P&G Health manufactures vitamins, minerals and nutritional supplements for use in healthcare. Owing to 10% sales growth for the financial year, the company’s board of directors proposed a final dividend of Rs. 11.50 per equity share in the meeting held on August 29, 2022.
The company in a regulatory filing said, “We are pleased to inform you that the Board of Directors of the Company in its meeting held today, has, inter alia, recommended a final dividend of Rs.11.50 per equity share for the financial year. Expired on 30th June, 2022. Dividend will be paid from 28th November, 2022 to 18th December, 2022 on the approval of the members at the 55th Annual General Meeting.
The company reported revenue from the operations of 295.89 crore in the quarter ended June 2022 In the corresponding quarter of the previous year and for the year ended the company has recorded sales revenue of 1114.41 crore as compared to 1008.73 crore in the financial year ended 30 June 2022, 10% more than a year ago. Profit After Tax (PAT) for the year ended June 30, 2022, stands at Rs 193 crore, 9% higher than a year ago. The company reported K PAT for the quarter ended June 2022 41.19 crore as compared to 33.89 crore in the quarter ended June 2021, an increase of 22%. For the quarter ended June 2022, the company has reported Profit Before Tax (PBT) of 54.65 crore as compared to 43.53 crore in the quarter ended June 2021, registering a growth of 26%.
Milind Thatte, Managing Director, P&G Health India said, “We have registered steady growth in revenue in the recent quarters in a challenging environment with the industry facing adverse conditions across multiple categories. It is the result of extensive efforts on all fronts to improve awareness and access to our superior, quality products and to better serve our customers, consumers, partners and communities. We continued our efforts to create awareness through integrated campaigns encouraging consumers to identify symptoms and seek timely treatment. Our team spearheads scientific education efforts for health practitioners through accredited seminars, roundtable conferences, and conferences with major medical and pharmacy associations. This year, we also launched ‘P&G Health Academy’, a virtual platform that brings together health experts from around the world to share, share and learn. We strengthened our go-to-market strategy through new initiatives aimed at increasing reach and distribution. We continue to invest in strengthening public health through our flagship CSR program ‘SEHAT’ (Earth Health) with nine bespoke initiatives, making strong progress on gender diversity, equality and inclusion through our i-RISE program “
The company said in a regulatory filing that “the board of directors has recommended a final dividend”. 11.50 per equity share for the financial year ended June 30, 2022. Keeping in view the interim dividend of 41 per share, the total dividend payout for the financial year will be 52.50 per share, subject to the approval of the final dividend by the shareholders of the company in the ensuing 55th Annual General Meeting.”
Shares of Procter & Gamble Health Ltd closed today 4,210.00 each, up 0.95% from the previous close. On a YTD basis, the stock has fallen 19.83% so far in 2022.
catch all business News, market news, today’s fresh news events and breaking news Updates on Live Mint. download mint news app To get daily market updates.